BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26060989)

  • 1. Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer.
    Cocco E; Shapiro EM; Gasparrini S; Lopez S; Schwab CL; Bellone S; Bortolomai I; Sumi NJ; Bonazzoli E; Nicoletti R; Deng Y; Saltzman WM; Zeiss CJ; Centritto F; Black JD; Silasi DA; Ratner E; Azodi M; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Int J Cancer; 2015 Dec; 137(11):2618-29. PubMed ID: 26060989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer.
    Cocco E; Casagrande F; Bellone S; Richter CE; Bellone M; Todeschini P; Holmberg JC; Fu HH; Montagna MK; Mor G; Schwartz PE; Arin-Silasi D; Azoudi M; Rutherford TJ; Abu-Khalaf M; Pecorelli S; Santin AD
    BMC Cancer; 2010 Jul; 10():349. PubMed ID: 20598131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
    Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Casagrande F; Cocco E; Bellone S; Richter CE; Bellone M; Todeschini P; Siegel E; Varughese J; Arin-Silasi D; Azodi M; Rutherford TJ; Pecorelli S; Schwartz PE; Santin AD
    Cancer; 2011 Dec; 117(24):5519-28. PubMed ID: 21692061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity of Clostridium perfringens enterotoxin depends on the conditions of claudin-4 in ovarian carcinoma cells.
    Tanaka S; Aoyama T; Ogawa M; Takasawa A; Murata M; Osanai M; Saito T; Sawada N
    Exp Cell Res; 2018 Oct; 371(1):278-286. PubMed ID: 30142326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers.
    Black JD; Lopez S; Cocco E; Schwab CL; English DP; Santin AD
    Toxins (Basel); 2015 Apr; 7(4):1116-25. PubMed ID: 25835384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue distribution and safety evaluation of a claudin-targeting molecule, the C-terminal fragment of Clostridium perfringens enterotoxin.
    Li X; Saeki R; Watari A; Yagi K; Kondoh M
    Eur J Pharm Sci; 2014 Feb; 52():132-7. PubMed ID: 24231339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).
    Santin AD; Bellone S; Marizzoni M; Palmieri M; Siegel ER; McKenney JK; Hennings L; Comper F; Bandiera E; Pecorelli S
    Cancer; 2007 Apr; 109(7):1312-22. PubMed ID: 17326053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.
    Cocco E; Deng Y; Shapiro EM; Bortolomai I; Lopez S; Lin K; Bellone S; Cui J; Menderes G; Black JD; Schwab CL; Bonazzoli E; Yang F; Predolini F; Zammataro L; Altwerger G; de Haydu C; Clark M; Alvarenga J; Ratner E; Azodi M; Silasi DA; Schwartz PE; Litkouhi B; Saltzman WM; Santin AD
    Mol Cancer Ther; 2017 Feb; 16(2):323-333. PubMed ID: 27956521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy.
    Pahle J; Menzel L; Niesler N; Kobelt D; Aumann J; Rivera M; Walther W
    BMC Cancer; 2017 Feb; 17(1):129. PubMed ID: 28193196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting claudin-overexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin.
    Piontek A; Eichner M; Zwanziger D; Beier LS; Protze J; Walther W; Theurer S; Schmid KW; Führer-Sakel D; Piontek J; Krause G
    Mol Oncol; 2020 Feb; 14(2):261-276. PubMed ID: 31825142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy.
    English DP; Santin AD
    Int J Mol Sci; 2013 May; 14(5):10412-37. PubMed ID: 23685873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions.
    Neesse A; Hahnenkamp A; Griesmann H; Buchholz M; Hahn SA; Maghnouj A; Fendrich V; Ring J; Sipos B; Tuveson DA; Bremer C; Gress TM; Michl P
    Gut; 2013 Jul; 62(7):1034-43. PubMed ID: 22677720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors.
    Walther W; Petkov S; Kuvardina ON; Aumann J; Kobelt D; Fichtner I; Lemm M; Piontek J; Blasig IE; Stein U; Schlag PM
    Gene Ther; 2012 May; 19(5):494-503. PubMed ID: 21975465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin.
    Litkouhi B; Kwong J; Lo CM; Smedley JG; McClane BA; Aponte M; Gao Z; Sarno JL; Hinners J; Welch WR; Berkowitz RS; Mok SC; Garner EI
    Neoplasia; 2007 Apr; 9(4):304-14. PubMed ID: 17460774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.
    Gao Z; Xu X; McClane B; Zeng Q; Litkouhi B; Welch WR; Berkowitz RS; Mok SC; Garner EI
    Clin Cancer Res; 2011 Mar; 17(5):1065-74. PubMed ID: 21123456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas.
    Santin AD; Bellone S; Siegel ER; McKenney JK; Thomas M; Roman JJ; Burnett A; Tognon G; Bandiera E; Pecorelli S
    Clin Cancer Res; 2007 Jun; 13(11):3339-46. PubMed ID: 17545541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer.
    Gabig TG; Waltzer WC; Whyard T; Romanov V
    Biochem Biophys Res Commun; 2016 Sep; 478(2):887-92. PubMed ID: 27520378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor effect of a recombinant Bifidobacterium strain secreting a claudin-targeting molecule in a mouse breast cancer model.
    Shimizu Y; Isoda K; Taira Y; Taira I; Kondoh M; Ishida I
    Eur J Pharmacol; 2020 Nov; 887():173596. PubMed ID: 32979353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin.
    Ebihara C; Kondoh M; Hasuike N; Harada M; Mizuguchi H; Horiguchi Y; Fujii M; Watanabe Y
    J Pharmacol Exp Ther; 2006 Jan; 316(1):255-60. PubMed ID: 16183701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.